Advertisement


Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib and Patient-Reported Outcomes

IASLC 2020 World Conference on Lung Cancer in Singapore

Advertisement

Roy S. Herbst, MD, PhD, of Yale University, discusses two key abstracts from the ADAURA trial: the use of osimertinib as adjuvant therapy for resected EGFR-mutated non–small cell lung cancer; and patient-reported outcomes, which showed a benefit in disease-free survival and maintenance of health-related quality of life in patients with resected stage IB to IIIA disease (Abstracts OA06.04 and OA06.03).



Related Videos

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: Pembrolizumab, Platinum Chemotherapy, and Radiotherapy in Advanced Disease

Martin Reck, MD, PhD, of the LungenClinic, discusses the results from KEYNOTE-799, which explored a new strategy to increase the intensity of treatment in patients with unres...

Lung Cancer

Jill Feldman: A Determined Cancer Survivor Shares Her Story of a Family Devastated by Lung Cancer

Jill Feldman, a patient advocate who has lost five family members to lung cancer and is herself a 12-year cancer survivor living with EGFR-positive disease, describe...

Lung Cancer
Issues in Oncology

Jill Feldman on Diversifying the Criteria for Inclusion in Clinical Trials

Jill Feldman, a patient advocate and lung cancer survivor, discusses the current challenges and potential solutions to including more people of color and those in underserved...

Solid Tumors
Immunotherapy

Prasad S. Adusumilli, MD, on Cell Therapy for Solid Tumors

Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses ongoing CAR T-cell therapy clinical trials for solid tumors, the key determinants of success fo...

Lung Cancer
Immunotherapy

Fred R. Hirsch, MD, PhD, on Lung Cancer: Survival and Tumor Mutation Burden

Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked...

Advertisement

Advertisement



Advertisement